We are live on
!
Find out more
ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
1-Year Est. Return
44.72%
This Fund
S&P 500
This Quarter
Est. Return
+3.13%
1 Year Est. Return
+44.72%
3 Year Est. Return
+299.95%
5 Year Est. Return
+628.83%
10 Year Est. Return
–
AUM
$145M
AUM Growth
-$47.9M
(-25%)
Cap. Flow
-$43.6M
Cap. Flow
% of AUM
-29.96%
Top 10 Holdings %
Top 10 Hldgs %
61.57%
Holding
40
New
11
Increased
4
Reduced
15
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$11.3M |
| 2 |
Aclaris Therapeutics
ACRS
|
+$7.17M |
| 3 |
Alkermes
ALKS
|
+$6.79M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$5.41M |
| 5 |
Kymera Therapeutics
KYMR
|
+$5.36M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$11.6M |
| 2 |
UnitedHealth
UNH
|
+$10.9M |
| 3 |
NSTG
NanoString Technologies, Inc.
NSTG
|
+$9.37M |
| 4 |
Kura Oncology
KURA
|
+$7.84M |
| 5 |
Arcus Biosciences
RCUS
|
+$6.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.4% |
| 2 | Financials | 0.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Centene
CNC
$31.6B
| $12M | 8.25% |
+164,489
| New | +$11.3M |
|
2
AstraZeneca
AZN
$263B
| $10.5M | 7.25% |
88,005
-21,454
| -20% | -$2.35M |
|
3
Sotera Health
SHC
$4.92B
| $10.2M | 7.02% |
421,341
-45,936
| -10% | -$1.13M |
|
|
ARNA
4
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $9.7M | 6.67% |
142,246
-20,889
| -13% | -$1.36M |
|
|
MRTX
5
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $9.37M | 6.44% |
57,979
+33,716
| +139% | +$5.41M |
|
6
Jazz Pharmaceuticals
JAZZ
$16B
| $9.36M | 6.44% |
52,702
-21,462
| -29% | -$3.72M |
|
7
Insulet
PODD
$11.4B
| $7.95M | 5.46% |
28,943
-14,240
| -33% | -$3.87M |
|
|
8
Alkermes
ALKS
$8.79B
| $7.49M | 5.15% |
+305,245
| New | +$6.79M |
|
9
Adaptive Biotechnologies
ADPT
$3.61B
| $6.87M | 4.72% |
168,172
-119,318
| -42% | -$4.64M |
|
|
EPIX
10
DELISTED
ESSA Pharma
EPIX
| $6.07M | 4.17% |
212,525
-71,934
| -25% | -$2.09M |
|
|
11
Kymera Therapeutics
KYMR
$9.05B
| $5.98M | 4.11% |
+123,363
| New | +$5.36M |
|
|
12
Aclaris Therapeutics
ACRS
$750M
| $5.55M | 3.81% |
+315,834
| New | +$7.17M |
|
|
MREO
13
Mereo BioPharma
MREO
$48.2M
| $5.13M | 3.53% |
1,618,328
+555,064
| +52% | +$1.86M |
|
14
Biodesix
BDSX
$230M
| $5.04M | 3.46% |
19,069
-3,134
| -14% | -$985K |
|
|
ASLN
15
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
| $3.94M | 2.71% |
29,852
-3,962
| -12% | -$495K |
|
16
PMV Pharmaceuticals
PMVP
$62.9M
| $3.48M | 2.39% |
101,776
-16,352
| -14% | -$546K |
|
|
HOLX
17
DELISTED
Hologic
HOLX
| $3.08M | 2.12% |
+46,184
| New | +$3.09M |
|
18
Guardant Health
GH
$19.3B
| $3.04M | 2.09% |
24,443
-37,466
| -61% | -$5.04M |
|
|
FOLD
19
DELISTED
Amicus Therapeutics
FOLD
| $2.88M | 1.98% |
+299,284
| New | +$2.92M |
|
|
AVDL
20
DELISTED
Avadel Pharmaceuticals
AVDL
| $2.69M | 1.85% |
399,776
-312,595
| -44% | -$2.48M |
|
21
argenx
ARGX
$55.6B
| $2.44M | 1.68% |
+8,104
| New | +$2.3M |
|
22
Forte Biosciences
FBRX
$1.57B
| $2.23M | 1.53% |
2,656
+528
| +25% | +$476K |
|
23
Bio-Rad Laboratories Class A
BIO
$8.47B
| $1.92M | 1.32% |
+2,979
| New | +$1.81M |
|
|
ITOS
24
DELISTED
iTeos Therapeutics
ITOS
| $1.57M | 1.08% |
61,248
-41,038
| -40% | -$978K |
|
|
LENZ
25
LENZ Therapeutics
LENZ
$179M
| $1.57M | 1.08% |
+7,291
| New | +$1.27M |
|
Similar funds
FAC
SWM
MC
KM
TI
GC
REMS
NM
Asymmetry Capital Management's Q2 2021 Portfolio in Review
As of Q2 2021, Asymmetry Capital Management held 40 positions worth $145M, down 25% from $193M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
Asymmetry Capital Management withdrew a net $43.6M in Q2 2021, closing 10 positions and reducing 15 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $11.6M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.
Against the trend, Asymmetry Capital Management opened a new position in Centene worth $12M.
- Asymmetry Capital Management's largest Q2 2021 buy was Centene: 164,489 shares worth $12M.
- Asymmetry Capital Management added most to Mirati Therapeutics, Inc. Common Stock in Q2 2021, an estimated $5.41M increase.
- Asymmetry Capital Management's biggest Q2 2021 reduction was Guardant Health, cutting an estimated $5.04M.
- Asymmetry Capital Management fully exited Vertex Pharmaceuticals in Q2 2021, selling an estimated $11.6M.
- Asymmetry Capital Management's ten largest holdings make up 62% of its $145M portfolio in Q2 2021.
- Asymmetry Capital Management opened 11 new positions and closed 10 in Q2 2021.
- Asymmetry Capital Management's portfolio value fell 25% quarter-over-quarter to $145M.
Based on Asymmetry Capital Management's 13F filing for Q2 2021, filed 28 Jul 2021.